Headlines

Eli Lilly's (LLY) triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

Newsquawk Staff ·

  • In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric surgery
  • Individuals with a baseline BMI ≥35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks

Related headlines